Statement of Ownership (sc 13g)
March 01 2021 - 5:30PM
Edgar (US Regulatory)
7,4
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. )*
Evolus, Inc.
(Name
of Issuer)
Common
stock, par value $0.00001 per share
(Title
of Class of Securities)
30052C107
(CUSIP
Number)
February
18, 2021
(Date
of Event Which Requires Filing of this Statement)
Check
the appropriate box to designate the rule pursuant to which this Schedule is filed:
☐
Rule 13d-1(b)
☒
Rule 13d-1(c)
☐
Rule 13d-1(d)
*
The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to
the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided
in a prior cover page.
The
information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section
18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the Notes).
CUSIP
No. 30052C107
|
13G
|
Page
2 of 5 Pages
|
1
|
NAME
OF REPORTING PERSON
I.R.S.
IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Medytox
Inc.
|
2
|
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a)
☐
(b) ☐
|
3
|
SEC
USE ONLY
|
4
|
CITIZENSHIP
OR PLACE OF ORGANIZATION
Republic of Korea
|
NUMBER
OF
SHARES
BENEFICIALLY
OWNED
BY
EACH
REPORTING
PERSON
WITH:
|
5
|
SOLE
VOTING POWER
6,762,652 (1)
|
6
|
SHARED
VOTING POWER
0
|
7
|
SOLE
DISPOSITIVE POWER
6,762,652
|
8
|
SHARED
DISPOSITIVE POWER
0
|
9
|
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
6,762,652
|
10
|
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐
|
11
|
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
16.7% (2)
|
12
|
TYPE
OF REPORTING PERSON
CO
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
As part of the Share Issuance Agreement, effective February 18, 2021, between the Issuer and the Reporting Person (the “Share
Issuance Agreement”), the Issuer issued 6,762,652 shares of common stock of the Issuer, par value $0.00001 (“Common
Stock”) to the Reporting Person on February 18, 2021.
(2)
Based on a total of 40,592,832, which is equal to (i) 33,830,180 shares of Common Stock outstanding as of February 14, 2021, as
reported by the Issuer in the Share Issuance Agreement plus (ii) the 6,762,652 shares of Common Stock issued to the Reporting
Person pursuant to the Share Issuance.
|
|
|
Item 1(a).
|
Name of Issuer:
|
Evolus,
Inc., a Delaware corporation
|
Item 1(b).
|
Address of Issuer’s Principal Executive
Offices:
|
520
Newport Center Drive, Suite 1200
Newport
Beach, CA 92660
|
Item 2(a).
|
Name of Person Filing:
|
Medytox
Inc.
|
Items 2(b).
|
Address of Principal
Business Office or, if none, Residence:
|
Medytox
Inc.
78
Gangni 1-gil Ochang-eup
Cheongwon-gu
Cheongju-si
Chungcheongbuk-do
28126
Republic
of Korea
Medytox
Inc. is a company organized under the laws of the Republic of Korea.
|
Item 2(d).
|
Title of Class of Securities:
|
Common
stock, par value $0.00001 per share
|
Item 2(e).
|
CUSIP
NUMBER:
30052C107
|
|
Item 3.
|
If This Statement
is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
|
Not
Applicable.
|
(a)
|
Amount
beneficially owned:
Medytox
Inc. – 6,762,652
|
|
(b)
|
Percent
of Class:
16.7%
|
|
(c)
|
Number of shares as to which such person has:
|
|
(i)
|
Sole
power to vote or to direct the vote:
6,762,652
|
|
(ii)
|
Shared
power to vote or to direct the vote:
0
|
|
(iii)
|
Sole
power to dispose or to direct the disposition of:
6,762,652
|
|
(iv)
|
Shared
power to dispose or to direct the disposition of:
0
|
|
Item 5.
|
Ownership of
5 Percent or Less of a Class.
|
Not
applicable.
|
Item 6.
|
Ownership of
More than 5 Percent on Behalf of Another Person.
|
Not
applicable.
|
Item 7.
|
Identification
and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control
Person.
|
Not
applicable.
|
Item 8.
|
Identification
and Classification of Members of the Group.
|
Not
applicable.
|
Item 9.
|
Notice of Dissolution
of Group.
|
Not
applicable.
By
signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are
not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were
not acquired and not held in connection with or as a participant in any transaction having that purpose or effect, other than
in connection with a nomination under §240.14a–11.
SIGNATURE
After
reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true,
complete and correct.
Dated:
March 1, 2021
|
MEDYTOX INC.
|
|
|
|
|
|
By:
|
/s/
Hyunho Jung
|
|
|
Name:
|
Hyunho Jung
|
|
Title:
|
Chief Executive Officer
|
Evolus (NASDAQ:EOLS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Evolus (NASDAQ:EOLS)
Historical Stock Chart
From Apr 2023 to Apr 2024